Response of early active rheumatoid arthritis to tumor necrosis factor inhibitors: Evaluation by magnetic resonance imaging

Modern Rheumatology

Volumn 19, Issue 1, 2009, Pages 20-26

  Hirose, Wataru ^a   Nishikawa, Kenichiro ^a   Hirose, Masuko ^a   Nanki, Toshihiro ^b   Sugimoto, Hideharu ^c  

^a Hirose Clinic   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Early rheumatoid arthritis; Magnetic resonance imaging; Tumor necrosis factor inhibitor

Indexed keywords

BUCILLAMINE; C REACTIVE PROTEIN; ETANERCEPT; GADOLINIUM PENTETATE; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; BONE EROSION; BONE MARROW EDEMA; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DRUG RESPONSE; EDEMA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HAND RADIOGRAPHY; HUMAN; JOINT DESTRUCTION; JOINT SWELLING; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYNOVITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 3; METHOTREXATE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 60149084661     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-008-0114-4     Document Type: Article

References (23)

1. Ostegaard M, Hansen M, Stoltenberg M, Jensen KE, Szkudlarek M, Pedersen-Zbinden B, et al. New radiographic bone erosions in the wrists of patients with rheumatoid arthritis are detectable with magnetic resonance imaging a median of two years earlier. Arthritis Rheum. 2003;48:2128-31.
2. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
3. Sharp JT, Young DY, Bluhm GB, Brower AC, Corbett M, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum. 1985;28:1326-35.
4. Plant MJ, Saklatvala J, Borg AA, Jones PW, Dawes PT. Measurement and prediction of radiological progression in early rheumatoid arthritis. J Rheumatol. 1994;21:1808-13.
5. Ostergaard M, Edmonds J, McQeen F, Peterfy C, Lassere M, Ejbjerg B, et al. An introduction to the EULAR-OMERACT rheumatoid arthritis MRI reference image atlas. Ann Rheum Dis. 2005;64(Suppl 1):i3-i7.
6. Cohen J. Statistical power analysis for the behavioral sciences. 2nd edn. Hillsdale: Lawrence Erlbaum; 1988.
7. Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007;17:451-8.
8. Revised guidelines for TNF inhibitor therapy (published in January 2008). Tokyo: Japan College of Rheumatology
9. Smyth CJ. Therapy of rheumatoid arthritis. A pyramidal plan. Postgrad Med. 1972;51:31-9.
10. Weinblat ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985;312:818-22.
11. Williams HJ, Willkens RF, Samuelson CO Jr, Alarcon GA, Guttadauria M, Yarboro C, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. Arthritis Rheum. 1985;28:721-30.
12. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt K, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253-9.
13. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor αmonoclonal antibody) versus placebo in rheumatoid arthritis receiving concomitant methotrexate: A randomized phase III trial. Lancet. 1999;354:1932-9.
14. Klareskog L, van der Heijde D, Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blinded randomised controlled trial. Lancet. 2004;363:675-81.
15. St. Clair EW, van der Heijde DMFM, Smolen JF, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum. 2004;50:3432-43.
16. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission. Arthritis Rheum. 2006;54:3761-73.
17. Gaylis NB, Needell SD, Rudensky D. Comparison of in-office magnetic resonance imaging versus conventional radiography in detecting changes in erosions after one year of infliximab therapy in patients with rheumatoid arthritis. Mod Rheumatol. 2007;17:273-8.
18. Bathon JM, Martin RW, Fleishmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586-93.
19. Nell VPK, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology. 2004;43:906-14.
20. Schirmer C, Scheel AK, Althoff CE, Schink T, Eshed I, Lembcke A, et al. Diagnostic quality and scoring of synovitis, tenosynovitis and erosions in low-field MRI of patients with rheumatoid arthritis: A comparison with conventional MRI. Ann Rheum Dis. 2007;66:522-9.
21. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal. Results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:27-35.
22. Martinez-Martinez MU, Cuevas-Orta E, Reyes-Vaca G, Baranda L, Gonzalez-Amaro R, and Abud-Mendoza. Magnetic resonance imaging in patients with rheumatoid arthritis with complete remission treated with disease-modifying antirheumatic drugs or anti-tumour necrosis factor α agents: Ann Rheum Dis 2007;66:134-5.
23. Conaghan PG, McQeen FM, Peterfy CG, Lassere MND, Ejbjerg B, Bird P, et al. The evidence for magnetic resonance imaging as an outcome measure in proof-of-concept rheumatoid arthritis studies. J Rheumatol. 2005;32:2465-9.